BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20230101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240130
DTEND;VALUE=DATE:20240202
DTSTAMP:20260516T004551
CREATED:20231206T112751Z
LAST-MODIFIED:20231206T112751Z
UID:38270-1706572800-1706831999@www.pharmajournalist.com
SUMMARY:2nd Next Generation Ophthalmic Drug Delivery Summit
DESCRIPTION:The 2nd Annual Next Generation Ophthalmic Drug Delivery Summit is returning to San Francisco this January to unite 90+ device engineers\, biochemists\, preclinical and clinical experts as they discuss how they are optimizing longer-lasting and less invasive delivery to the back of the eye to reduce patient concerns and burden on healthcare systems caused by frequent drug administration. \nJoin 23+ expert speakers from the likes of AbbVie\, Boehringer Ingelheim\, Bayer\, Genentech\, Janssen\, Novartis\, and Clearside Biomedical at the only industry-dedicated event focusing on overcoming key translational challenges of developing and implementing novel delivery technology as they progress their ophthalmic pipelines to the clinic. \nTo know more visit: https://ter.li/o3pq3n
URL:http://www.pharmajournalist.com/event/2nd-next-generation-ophthalmic-drug-delivery-summit/
LOCATION:The Marker San Francisco\, 501 Geary St\, San Francisco\, CA\, 94102\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240130
DTEND;VALUE=DATE:20240202
DTSTAMP:20260516T004551
CREATED:20240105T091432Z
LAST-MODIFIED:20240105T091432Z
UID:38450-1706572800-1706831999@www.pharmajournalist.com
SUMMARY:8th Microbiome Movement - Drug Development Summit Europe
DESCRIPTION:As Europe’s premiere microbiome conference tightly focused on the development of microbiome-based therapeutics\, this is your prime opportunity to expand your microbiome-based drug development capabilities and business potential as we aim to deliver clinical results and ensure therapeutic microbiome approval in Europe. \nNo matter what stage of development you’re focusing on\, this is your one-stop shop for microbiome-based drug development from early discovery to late-phase manufacturing! \nWhat’s New for 2024: \n\nHighlighting early-stage organisations and their novel technologies in our brand-new technology showcase where we welcome Centre for Genomic Regulation\, Recolony and Synflora to give quick fire presentations to showcase their work.\nDiscover our new enabling technologies track to learn more about the exciting artificial intelligence\, integrated -omics analysis and improved manufacturing capabilities among the other technologies that are accelerating microbiome-based drug development.\nStrengthen your regulatory understanding and enhance decision-making by uncovering global regulations to address updated SoHo frameworks\, explore considerations for engineered microbes and consolidate agencies interactions\n\nTo know more visit: https://ter.li/zi3xwf
URL:http://www.pharmajournalist.com/event/8th-microbiome-movement-drug-development-summit-europe/
LOCATION:Hotel Barceló Sants\, Pl. dels Països Catalans\, s/n\, 08014\, Barcelona\, 08014\, Spain
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240213
DTEND;VALUE=DATE:20240216
DTSTAMP:20260516T004551
CREATED:20231101T110512Z
LAST-MODIFIED:20231101T111904Z
UID:38062-1707782400-1708041599@www.pharmajournalist.com
SUMMARY:4th Gene Therapy Comparability Summit
DESCRIPTION:As we witness a surge in later-stage clinical trials within the gene therapy industry\, the spotlight on comparability has never been brighter. That’s why we’re thrilled to announce the return of the 4th Gene Therapy Comparability Summit\, taking place in Boston\, MA\, February 13-15. \n \nThis event is your gateway to uncovering how to implement effective comparability studies to overcome strategic and technical hurdles to expedite more gene therapy approvals. \nWhat to expect at the 2024 meeting: \n\nGain valuable insights from CSL Behring\, Bayer\, Ultragenyx\, and other industry leaders on the transition to in-house manufacturing\, effective variability management\, and ensuring consistency across multiple facilities.\nExamine Sarepta’s considerations before and after receiving regulatory approval and investigate the distinctions among global regulatory agencies with insights from Novartis\, Sarepta\, and Adverum.\nStrengthen your analytical toolbox and enhance comparability studies through case studies and strategies to reduce variability with AskBio and BioMarin.\nStay ahead of the latest advancements in process development for improved characterization and analysis of AAV-gene therapies\, with a focus on minimizing process alterations\, featuring contributions from Abbvie and Spark Therapeutics.\nHarness strategic insights from cell therapy study design\, innovative analytical techniques\, and regulatory expertise to enhance your gene therapy comparability protocols\, supported by Novartis.\n\nDon’t miss this unparalleled opportunity to stay at the forefront of gene therapy comparability. Join us and gain the knowledge\, tools\, and connections to secure your gene therapy approval. \nDownload the full event guide here to view the full expert speaker line up and see who else you will meet: https://ter.li/rrefvp
URL:http://www.pharmajournalist.com/event/4th-gene-therapy-comparability-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240213
DTEND;VALUE=DATE:20240216
DTSTAMP:20260516T004551
CREATED:20231123T125801Z
LAST-MODIFIED:20240117T112321Z
UID:38209-1707782400-1708041599@www.pharmajournalist.com
SUMMARY:3rd mRNA Analytical Development Summit
DESCRIPTION:100+ Technical mRNA Specialists | 35+ Expert Speakers \nAs access to faster and higher-throughput analytical methods becomes increasingly vital\, it is critical that we employ superior analytical approaches for mRNA-based therapeutics and vaccines to ensure high quality and effective drugs are approved\, whilst adhering to regulatory guidelines. \nThe 3rd mRNA Analytical Development Summit returns to Boston in February to seek and discuss new guidelines and identify a path forward with tangible best practices to ensure reliable analytical methods are guiding mRNA production\, purification and formulation optimization for approval of high quality\, compliant mRNA drugs for patients in need. \nDownload the three day program here: https://ter.li/pi54tj \n100+ Heads\, Directors and Senior Scientists of Analytical Development\, Quality Control\, CMC and Regulatory Affairs will deep dive into analytical development techniques and challenges within mRNA drug product and drug substance\, eager to glean insights into future analytical methods to safeguard regulatory submissions in 2024 and beyond. \nJoin them and register your place here: https://ter.li/d6nqe3
URL:http://www.pharmajournalist.com/event/3rd-mrna-analytical-development-summit/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240220
DTEND;VALUE=DATE:20240223
DTSTAMP:20260516T004551
CREATED:20231120T110619Z
LAST-MODIFIED:20231120T110619Z
UID:38173-1708387200-1708646399@www.pharmajournalist.com
SUMMARY:6th Annual CRISPR AgBio Congress
DESCRIPTION:The 6th Annual CRISPR AgBio Congress is back on February 20-22\, 2024 (Raleigh\, NC). The dedicated congress that unites industry stakeholders across Agbiotech\, big seed\, distributors\, and investors\, to assess this new regulatory terrain\, examine recent scientific breakthroughs\, and strategize the journey of CRISPR products from editing to delivery\, field to shelf. \nDiscover the full program here. \nBack for its 6th edition\, join the likes of the Pairwise CEO\, and advisors at USDA and EPA as we: \n\nDiscover the latest on the global and US regulatory landscape\, uncover what’s new for standardizing approval processes\, and tackle regulatory compliance for your products\nUncover novel gene editing tools and CRISPR technologies\, AI\, Cas-12\, and CRISPR-enabled breeding and trait discovery tools to address unmet agricultural challenges\nExplore CRISPR product commercialization and effective market targeting strategies for rapid adoption\nTransform agriculture with sustainable crop solutions: explore alternative fuels and precision breeding for enhanced crop sustainability\nUnpick how to enhance the adaptability\, productivity\, and nutrition of orphan and non-model crops such as potatoes\, and strawberries to accelerate breeding and cut costs\n\nView your copy here to find the jam-packed agenda\, with exclusive case studies led by industry giants and regulatory bodies to help you commercialize regulatory-approved gene-edited agriculture products. \nJoin 80+ C-level leaders\, researcher heads\, Molecular Biologists\, Regulatory Experts\, and Product Developers from major seed companies\, innovative Agbiotechs\, influential academic institutions\, and regulatory bodies and be part of the conversation in 2024. \nHere’s what past attendees had to say: \n“Great quality of presentations and coherent style of participants: scientists with key roles in their company and key relevant academic researchers” – Chief Executive Officer\, Meiogenx   \n“The arrangements for the conference\, quality of speakers\, and novel ways to encourage networking were great” – Senior Director\, Yield10 Bioscience
URL:http://www.pharmajournalist.com/event/6th-annual-crispr-agbio-congress/
LOCATION:Sheraton Raleigh Hotel\, 421 South Salisbury St\, Raleigh\, NC\, 27601\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.con
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240220
DTEND;VALUE=DATE:20240223
DTSTAMP:20260516T004551
CREATED:20240103T113819Z
LAST-MODIFIED:20240103T113819Z
UID:38417-1708387200-1708646399@www.pharmajournalist.com
SUMMARY:2nd Viral Vector Process Development & Manufacturing
DESCRIPTION:Viral Vector Process Development & Manufacturing Summit\nCreate Qualitative\, Accessible Treatments for Patients \nFollowing Ring Therapeutics’ injection of $86.5m to enhance novel viral vector capabilities\, and BMS’s viral vector facility coming online\, the viral vector market is forecasted to reach $12.8bn – not only in cell and gene therapies but also viral-vector-based vaccines and immunotherapies. \n \nWith the FDA’s fast-evolving quality assessment and lack of standard guidance\, and the continued challenge of viral vector recovery yield and purity\, the 2nd Viral Vector Process Development & Manufacturing Summit is your must-attend meeting in 2024 to help answer your burning questions to enhance process intensification capabilities while meeting regulatory agencies’ expectations. \nIn collaboration with Sarepta\, Ultragenyx\, Affinia Therapeutics\, and UCB\, we will unite 130+ pioneering viral vector up- and downstream process engineers\, MSAT\, CMC to tackle these challenges together. This is your definitive community to seek help from industry pioneers to expedite scale-up\, tech transfer\, and speed-to-clinic. Returning to Boston in February\, we are proud to expand the program into 2 tracks of content as the only industry-led\, end-to-end summit to align with your needs: \n\nDownstream process intensification\, including purification\, to improve recovery and yield\nPurity assessment to uphold GMP and product quality assessment\nDeep dive into upstream process development and cell line in relation to your viral vectors\, and assess platforming strategy\nRapid scale-up with robust analytical capabilities and improve your full:empty capsid ratio and reduce COGs\nMeet and evaluate solution providers and viral vector CDMOs\, including Lonza\, Chromatan\, Teknova\, and Genezen\, to forge long-term relationships\, ensuring tech transfer readiness\n\nIt’s worth clearing 3 days out of your office and joining this summit to leverage novel platform technologies such as continuous processing to improve viral vector manufacturing! \nTo know more visit: https://ter.li/fvlk3e
URL:http://www.pharmajournalist.com/event/2nd-viral-vector-process-development-manufacturing/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240226
DTEND;VALUE=DATE:20240229
DTSTAMP:20260516T004551
CREATED:20240213T102528Z
LAST-MODIFIED:20240213T102742Z
UID:38686-1708905600-1709164799@www.pharmajournalist.com
SUMMARY:3rd Next-Generation Conjugates Summit
DESCRIPTION:From Bristol Myers Squibb expanding their cardiovascular partnership with Avidity Biosciences’ antibody-oligonucleotide conjugate technology\, to Nurix and Seagen collaborating on a targeted protein degradation conjugate\, there is now a staggering amount of investment and collaboration in the novel conjugates space. \nAs highlighted above\, drug developers are pushing the boundaries of traditional ADCs by designing and developing novel targeting formats and payloads. Whilst the likes of VincerX Pharma\, Dyne Therapeuitcs and Alnylam are now awaiting clinical validation\, and others continue to innovate in conjugate design\, it is an exciting time for the next-generation conjugates field. \n \nCovering case-study led presentations on novel design concepts\, key translational and clinical development challenges\, and addressing challenging CMC roadblocks\, the Next-Generation Conjugates Summit is your only event uniting developers of a wide array of novel formats and payloads\, with conjugate modality types including antibody-oligonucleotide conjugates\, fragment-drug conjugates\, Targeted Radiopharmaceutical Conjugates\, small molecule-drug conjugates\, bispecific-drug conjugates and more! \nThis is the only event to unite 100+ drug developers from companies of different modality types that would not normally come together\, so make sure to join likeminded conjugate developers to learn\, collaborate and innovate and expand on the potential of conjugate drugs. \nLearn more here: https://ter.li/q5wf9x
URL:http://www.pharmajournalist.com/event/3rd-next-generation-conjugates-summit/
LOCATION:Hotel Commonwealth\, 500 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:adc@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240227
DTEND;VALUE=DATE:20240301
DTSTAMP:20260516T004551
CREATED:20231011T093613Z
LAST-MODIFIED:20240119T123110Z
UID:37931-1708992000-1709251199@www.pharmajournalist.com
SUMMARY:7th CAR-TCR Summit Europe
DESCRIPTION:Cell therapy continues to transform the oncology field\, and this year has also seen the translation of cell therapies’ curative potential into the autoimmune space. \nProviding your team with exclusive access to cutting-edge advances across pre-clinical platforms\, clinical advances\, and streamlined manufacturing\, the 7th CAR-TCR Summit Europe is your must-attend forum to stay at the forefront of these innovations.   \n300+ industry experts will brainstorm enhancing target discovery\, optimizing durability of response and identifying biomarkers to support recruitment\, automating production\, and accelerating analytical processes to reduce operational costs and turnaround times.   \nWith a new Biopharma & Investors Evening\, a new C-Level Think Tank\, new speakers and data from Mnemo Therpaeutics\, Cellectis\, Bambino Gesu Hospital and more\, can your team afford to miss out? \nTo know more visit: https://ter.li/6vgioi
URL:http://www.pharmajournalist.com/event/7th-car-tcr-summit-europe/
LOCATION:ExCeL London\, Royal Victoria Dock\, 1 Western Gateway\, London\, E16 1XL\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240227
DTEND;VALUE=DATE:20240301
DTSTAMP:20260516T004551
CREATED:20240111T102635Z
LAST-MODIFIED:20240111T102635Z
UID:38483-1708992000-1709251199@www.pharmajournalist.com
SUMMARY:6th Bacteriophage Therapy Summit
DESCRIPTION:The Bacteriophage Therapy Summit is the only global platform for industry-dominated phage drug developers. Actively engage with the likes of Merck\, Pfizer\, SNIPR Biome\, Locus Biosciences\, Phiogen\, AMR Action Fund and 90+ phage experts to demonstrate positive clinical data and patient outcomes. \nTake advantage of this unique opportunity to be a part of the dialogue\, meet phage leaders\, large pharma\, and venture capitalists to gain practical takeaways\, and demonstrate the clinical utility of your bacteriophage to form meaningful partnerships. \nJoin us for 3 days of unmissable content\, and accelerate your bacteriophage research into clinical\, meaningful and commercially viable therapies. \nCheck out the full event guide now: https://ter.li/jig8n0
URL:http://www.pharmajournalist.com/event/6th-bacteriophage-therapy-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR